Recensiones [Revista de Historia Económica Año XX Primavera-Verano 2002 n. 2 pp. 389-426]

Editada en la Fundación Empresa PúblicaManera, C: Història del creixement económic a Mallorca (1700-2000) (Por Luis Germán Zubero).-- Carmona, J., Colomé, J., Pan-Montojo, J., y Simpson, J. (eds.): Viñas, bodegas y mercados. El cambio técnico en la vitivinicultura española, 1830-1936 (Por Carmelo Pellejero).-- González Portilla, M. (ed.): Los orígenes de una metrópoli industrial: la ría de Bilbao (Por Carlos Larrinaga).-- Craig, L. A., y Fisher, D.: The European Macroeconomy: Growth, Integration and Cycles, 1500-1913 (Por Joan R. Roses).-- Sargent, T., y Velde, F.: The Big Problem of Small Change (Por José I. García de Paso.-- Andersen, B.: Technological Change and the Evolution of Corporate Innovation: The Structure of Patenting, 1880-1990 (Por Patricio Sáiz).-- Rotberg, R. (ed.): Patterns of Social Capital. Stability and Change in Historical Perspective (Por Blanca Sánchez Alonso).-- James, H.: The Deutsche Bank and the Nazi Economic War against the Jews (Por Pedro Fernández Sánchez).-- Battilossi, S., y Cassis, Y. (eds.): European Banks and the American Challenge. Competition and Cooperation in International Banking under Bretton Woods (Por Mª Ángeles Pons).-- Zeitlin, J., y Herrigel, G. (eds.): Americanization and its Limits. Reworking US Technology and Management in Post-war Europe and Japan (Por Nuria Puig)Publicad

Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

Altres ajuts: Spanish AIDS Research Network; European Funding for Regional Development (FEDER).Objectives: We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. Methods: The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. Results: The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). Conclusions: In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors

BACKGROUND: We aimed to describe the most frequently prescribed initial antiretroviral therapy (ART) regimens in recent years in HIV-positive persons in the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) and to investigate factors associated with the choice of each regimen. METHODS: We analyzed initial ART regimens prescribed in adults participating in CoRIS from 2014 to 2017. Only regimens prescribed in >5% of patients were considered. We used multivariable multinomial regression to estimate Relative Risk Ratios (RRRs) for the association between sociodemographic and clinical characteristics and the choice of the initial regimen. RESULTS: Among 2874 participants, abacavir(ABC)/lamivudine(3TC)/dolutegavir(DTG) was the most frequently prescribed regimen (32.1%), followed by tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir(EVG)/cobicistat(COBI) (14.9%), TDF/FTC/rilpivirine (RPV) (14.0%), tenofovir alafenamide (TAF)/FTC/EVG/COBI (13.7%), TDF/FTC+DTG (10.0%), TDF/FTC+darunavir/ritonavir or darunavir/cobicistat (bDRV) (9.8%) and TDF/FTC+raltegravir (RAL) (5.6%). Compared with ABC/3TC/DTG, starting TDF/FTC/RPV was less likely in patients with CD4100.000 copies/mL. TDF/FTC+DTG was more frequent in those with CD4100.000 copies/mL. TDF/FTC+RAL and TDF/FTC+bDRV were also more frequent among patients with CD4<200 cells//muL and with transmission categories other than men who have sex with men. Compared with ABC/3TC/DTG, the prescription of other initial ART regimens decreased from 2014-2015 to 2016-2017 with the exception of TDF/FTC+DTG. Differences in the choice of the initial ART regimen were observed by hospitals' location. CONCLUSIONS: The choice of initial ART regimens is consistent with Spanish guidelines' recommendations, but is also clearly influenced by physician's perception based on patient's clinical and sociodemographic variables and by the prescribing hospital location

Cambio social y cooperación en el Siglo XXI

Fundación Intervid

El Debate de Revista Internacional de Pensamiento Político. La Renta Básica. Entrevista

Tras la presentación del debate van a continuación las opiniones de los encuestados sobre la renta básica, contestando a un cuestionario de cinco preguntas. Los participantes forman un conjunto heterogéneo con distintas ideas acerca de la oportunidad, alcance y fundamentos de la renta básica. En el capítulo 8 de este número pueden encontrar un breve currículo de los encuestados, a quienes agradecemos desde la Redacción de RIPP la buena acogida y disponibilidad que han dispensado a la entrevista

Violence and Communication

Combining the terms "violence" and "communication" is a difficult, complex, incomplete, and perhaps impossible task, yet Violence and Communication seeks to demonstrate both generic and particular aspects of the expression and representation of violence. In a general sense, this expression and its consequences are explored in diverse global historical examples of violent events including the Holocaust, the genocide in Rwanda, and 9/11, as well as in thematic issues such as women and sexuality, poverty and inequality, and the Internet and violence. In a more particular sense, the work also addresses terrorist violence in the Basque Country, exploring specific topics such as its psychological effects in society and discursive consequences in the print media and on television. The book examines the representation of these different forms of violence in both the visual media (film, television, and photography) and the printed word (newspapers, literature, and so on). In short, the work attempts to visualize what have been often non-visible forms of violence, as well as critically analyze the multiple ways in which violence is represented and communicated.This book was published with generous financial support from the Basque Government.Introduction: Other Winds, New Dreams by Jose Antonio Mingolarra ? 1. The Four Horsemen of the Apocalypse: Audiovisual Models of Representing Violence by Imanol Zumalde ? 2. The Construction of the Stranger and Social Violence by Imanol Zubero ? 3. In the Limbo of the Invisible by Carmen Arocena and Nekane E. Zubiaur ? 4. New Reference Points for Communicating Violent Conflicts: Poverty and Inequality and Positions in the Current Debate on the Causes of Civil Wars by Alfonso DuBois ? 5. Violence and the Internet: New Technologies, Old Problems by Maialen Garmendia, Carmelo Garitaonandia, Gemma Martínez, and Miguel Ángel Casado ? 6. The Psychological Recovery Processes in Victims of Violence and Terrorist Acts by Juan de Dios Uriarte ? 7. Getting Closer: Photography, Death and Terrorist Violence in the Basque Country by Ramón Esparza and Nekane Parejo ? 8. The Basque Press and Terrorism, 1990-2009: From Telling the Facts to Complicity against ETA by José Ignacio Armentia and José María Caminos ? 9. Humor, Violence, and Infotainment in the Basque Country: The Vaya Semanita Phenomenon on Basque Public Television, 2003-2005 by Carmelo Moreno ? Index ? List of Contributor

Human immunodeficiency virus/hepatitis C virus coinfection in Spain : Prevalence and patient characteristics

The purpose of this study was to assess the prevalence of anti-hepatitis C virus (HCV) antibodies (Abs) and active HCV infection in human immunodeficiency virus (HIV)-infected (HIV+) patients in Spain in 2015. This was a cross-sectional study.Methods. The study was performed in 41 centers in 2015. Sample size was estimated for an accuracy of 2%, the number of patients from each hospital was determined by proportional allocation, and patients were selected using simple random sampling. The reference population was 35 791 patients, and the sample size was 1867 patients. Hepatitis C virus serostatus was known in 1843 patients (98.7%). Hepatitis C virus-Abs were detected in 695 patients (37.7%), in whom the main route of HIV acquisition was injection drug use (75.4%). Of these 695 patients, 402 had HCV RNA, 170 had had a sustained viral response (SVR) after anti-HCV therapy, and 102 cleared HCV spontaneously. Hepatitis C virus-ribonucleic acid results were unknown in 21 cases. Genotype distribution (known in 367 patients) was 1a in 143 patients (39.0%), 4 in 90 (24.5%) patients, 1b in 69 (18.8%) patients, 3 in 57 (15.5%) patients, 2 in 5 (1.4%) patients, and mixed in 3 (0.8%) patients. Liver cirrhosis was present in 93 patients (23.1%) with active HCV infection and in 39 (22.9%) patients with SVR after anti-HCV therapy. The prevalence of HCV-Abs and active HCV infection in HIV+ patients in Spain is 37.7% and 22.1%, respectively; these figures are significantly lower than those recorded in 2002 and 2009. The predominant genotypes in patients with active HCV infection were 1a and 4. A high percentage of patients had cirrhosis. Cirrhosis is also common in patients with SVR after anti-HCV therapy

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice : A multicentre cohort study

Background: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Methods: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml at the start of the regimen). Results: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure. Conclusions: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads